ArticleFrontiers in cardiovascular medicine2026
The impact of metabolic syndrome and triglyceride-glucose index on the risk of in-stent restenosis after percutaneous coronary intervention: a retrospective study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In-stent restenosis (ISR) remains a significant clinical challenge after percutaneous coronary intervention (PCI). Metabolic syndrome (MetS), characterized by a cluster of metabolic abnormalities, is increasingly recognized as a contributor to cardiovascular disease progression. This study aimed to investigate the association between MetS and the risk of ISR. Methods: We retrospectively reviewed the clinical and laboratory data of patients who underwent PCI and had follow-up angiography. Patients were categorized into MetS and non-MetS groups. MetS for comparisons of clinical characteristics and metabolic parameters. Cox and logistic regression analysis was used to identify independent risk factors for ISR. The predictive value of the triglyceride-glucose (TyG) index was evaluated using receiver operating characteristic (ROC) curve analysis. Results: A total of 565 patients were included, of whom 99 (17.5%) developed ISR and of whom 146 (25.8%) developed MetS. The prevalence of MetS was significantly higher in the ISR group than in the non-ISR group (46.5% vs. 21.5%). Patients with MetS had significantly higher fasting plasma glucose, triglyceride, TyG index, BMI, and blood pressure, but reduced high-density lipoprotein cholesterol. Multivariable logistic regression revealed MetS (OR = 2.43, 95% CI: 1.43-4.15) and TyG index (OR = 2.65, 95% CI: 1.55-4.52) as independent predictors of ISR. ROC analysis demonstrated that the TyG index had good discriminatory power for ISR (AUC = 0.70). Conclusion: Metabolic syndrome is significantly associated with an increased risk of ISR following PCI. The TyG index may serve as a useful marker for predicting ISR in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.